News Releases
May 19, 2022
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 05, 2022
Axcella Reports First Quarter Financial Results and Provides Business Update
Mar 30, 2022
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Mar 23, 2022
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
Mar 16, 2022
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
Feb 14, 2022
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
Feb 10, 2022
Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
Feb 07, 2022
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
Jan 06, 2022
Axcella Therapeutics Details Clinical and Operational Milestones for 2022
Jan 04, 2022
Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
Displaying 11 - 20 of 20